Skip to main content
SpringerLink
Log in

Effects of somatostatin and octreotide on cytokine and chemokine production by lipopolysaccharide-activated peripheral blood mononuclear cells

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background: Somatostatin plays an important role in the communication between the nervous, endocrine, and immune systems. Although somatostatin or its analogues have been shown to modulate a number of immune functions, their immunomodulatory effects are not uniform and are strongly dependent on the underlying cell system. Aim: The aim of our study was to analyze the immunomodulatory effects of somatostatin and its analogue octreotide on peripheral blood mononuclear cells (PBMC) in vitro. Materials/subjects: We used lipopolysaccharide-activated cells from normal glucose tolerant (NGT) subjects and from Type 2 diabetes mellitus (T2DM) patients as T2DM is associated with chronic, low-grade inflammation, and measured immune mediator release with multiplex bead-based assays. Results: Our data showed no statistically significant effects on the secretion of the cytokines interleukin (IL)-1β, IL-6, IL-10, IL-12, interferon-γ and tumor necrosis factor-α as well as the chemokines IL-8 and monocyte chemoattractant protein (MCP)-1, either on PBMC from T2DM patients or on those from NGT controls. However, a trend towards a dose-dependent biphasic effect was observed for IL-6, IL-10 and MCP-1 with reduced immune mediator levels at low and increased/unaltered levels at higher somatostatin or octreotide concentrations. These observations could not be explained by interference with cell viability or proliferation. Conclusions: We could not confirm immunomodulatory properties of somatostatin and octreotide on PBMC. Further analyses are necessary to explain the interaction between neuropeptides and the immune system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996, 334: 246–54.

    Article  PubMed  CAS  Google Scholar 

  2. ten Bokum AM, Hofland LJ, van Hagen PM. Somatostatin and somatostatin receptors in the immune system: a review. Eur Cytokine Netw 2000, 11: 161–76.

    PubMed  Google Scholar 

  3. Ryu SY, Jeong KS, Yoon WK, et al. Somatostatin and substance P induced in vivo by lipopolysaccharide and in peritoneal macrophages stimulated with lipopolysaccharide or interferon-gamma have differential effects on murine cytokine production. Neuroimmunomodulation 2000, 8: 25–30.

    Article  PubMed  CAS  Google Scholar 

  4. Lattuada D, Casnici C, Crotta K, et al. Inhibitory effect of pasireotide and octreotide on lymphocyte activation. J Neuroimmunol 2007, 182: 153–9.

    Article  PubMed  CAS  Google Scholar 

  5. Hernanz A, Tato E, De la Fuente M, de Miguel E, Arnalich F. Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha production by whole blood cells from healthy young and old subjects. J Neuroimmunol 1996, 71: 25–30.

    Article  PubMed  CAS  Google Scholar 

  6. Komorowski J, Stepien H. Somatostatin (SRIF) stimulates the release of interleukin-6 (IL-6) from human peripheral blood monocytes (PBM) in vitro. Neuropeptides 1995, 29: 77–81.

    Article  PubMed  CAS  Google Scholar 

  7. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005, 48: 1038–50.

    Article  PubMed  CAS  Google Scholar 

  8. Müller S, Martin S, Koenig W, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002, 45: 805–12.

    Article  PubMed  CAS  Google Scholar 

  9. Herder C, Baumert J, Thorand B, et al. Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984–2002. Diabetologia 2006, 49: 921–9.

    Article  PubMed  CAS  Google Scholar 

  10. Herder C, Kolb H, Koenig W, et al. Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4). Diabetes Care 2006, 29: 368–71.

    Article  PubMed  CAS  Google Scholar 

  11. Herder C, Klopp N, Baumert J, et al. Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984–2002. Diabetologia 2008, 51: 276–84.

    Article  PubMed  CAS  Google Scholar 

  12. Rose B, Herder C, Löffler H, Kolb H, Martin S. Combined activation of innate and T cell immunity for recognizing immunomodulatory properties of therapeutic agents. J Leukoc Biol 2004, 75: 624–30.

    Article  PubMed  CAS  Google Scholar 

  13. Herder C, Schneitler S, Rathmann W, et al. Low-grade inflammation, obesity, and insulin resistance in adolescents. J Clin Endocrinol Metab 2007, 92: 4569–74.

    Article  PubMed  CAS  Google Scholar 

  14. Blum AM, Metwali A, Mathew RC, et al. Granuloma T lymphocytes in murine schistosomiasis mansoni have somatostatin receptors and respond to somatostatin with decreased IFN-gamma secretion. J Immunol 1992, 149: 3621–6.

    PubMed  CAS  Google Scholar 

  15. Taylor AW, Yee DG. Somatostatin is an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci 2003, 44: 2644–9.

    Article  PubMed  Google Scholar 

  16. Casnici C, Lattuada D, Crotta K, et al. Effects of chimeric somatostatin-dopamine molecules on human peripheral blood lymphocytes activation. J Neuroimmunol 2006, 179: 9–17.

    Article  PubMed  CAS  Google Scholar 

  17. Muscettola M, Grasso G. Somatostatin and vasoactive intestinal peptide reduce interferon gamma production by human peripheral blood mononuclear cells. Immunobiology 1990, 180: 419–30.

    Article  PubMed  CAS  Google Scholar 

  18. Peluso G, Petillo O, Melone MA, et al. Modulation of cytokine production in activated human monocytes by somatostatin. Neuropeptides 1996, 30: 443–51.

    Article  PubMed  CAS  Google Scholar 

  19. Yousefi S, Vaziri N, Carandang G, et al. The paradoxical effects of somatostatin on the bioactivity and production of cytotoxins derived from human peripheral blood mononuclear cells. Br J Cancer 1991, 64: 243–6.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  20. Tang WF, Wang YG, Zhu L, et al. Effect of somatostatin on immune inflammatory response in patients with severe acute pancreatitis. J Dig Dis 2007, 8: 96–102.

    Article  PubMed  CAS  Google Scholar 

  21. Herberth G, Daegelmann C, Weber A, et al; LISAplus Study Group. Association of neuropeptides with Th1/Th2 balance and allergic sensitization in children. Clin Exp Allergy 2006, 36: 1408–16.

    Article  PubMed  CAS  Google Scholar 

  22. Agro A, Stanisz AM. Neuroimmunomodulation: classical and non-classical cellular activation. Adv Neuroimmunol 1995, 5: 311–9.

    Article  PubMed  CAS  Google Scholar 

  23. Elliott DE, Metwali A, Blum AM, Sandor M, Lynch R, Weinstock JV. T lymphocytes isolated from the hepatic granulomas of schisto-some-infected mice express somatostatin receptor subtype II (SSTR2) messenger RNA. J Immunol 1994, 153: 1180–6.

    PubMed  CAS  Google Scholar 

  24. Elliott DE, Li J, Blum AM, et al. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur J Immunol 1999, 29: 2454–63.

    Article  PubMed  CAS  Google Scholar 

  25. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997, 100: 2386–92.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  26. Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004, 80(Suppl 1): 47–50.

    Google Scholar 

  27. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999, 20: 157–98.

    Article  PubMed  CAS  Google Scholar 

  28. ter Veld F, Herder C, Mussmann R, Martin S, Kempf K. Somatostatin receptor expression in peripheral blood of type 2 diabetes mellitus patients. Horm Metab Res 2007, 39: 230–2.

    Article  PubMed  CAS  Google Scholar 

  29. Yan S, Li M, Chai H, et al. TNF-alpha decreases expression of somatostatin, somatostatin receptors, and cortistatin in human coronary endothelial cells. J Surg Res 2005, 123: 294–301.

    Article  PubMed  CAS  Google Scholar 

  30. Cipolletta C, Ryan KE, Hanna EV, Trimble ER. Activation of peripheral blood CD14+ monocytes occurs in diabetes. Diabetes 2005, 54: 2779–86.

    Article  PubMed  CAS  Google Scholar 

  31. Fogelstrand L, Hulthe J, Hultén LM, Wiklund O, Fagerberg B. Monocytic expression of CD14 and CD18, circulating adhesion molecules and inflammatory markers in women with diabetes mellitus and impaired glucose tolerance. Diabetologia 2004, 47: 1948–52.

    Article  PubMed  CAS  Google Scholar 

  32. Herder C, Haastert B, Muller-Scholze S, et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 2005, 54(Suppl 2): S11–7.

    Article  PubMed  CAS  Google Scholar 

  33. Herder C, Hauner H, Haastert B, et al. Hypoadiponectinemia and proinflammatory state: two sides of the same coin?: results from the Cooperative Health Research in the Region of Augsburg Survey 4 (KORA S4). Diabetes Care 2006, 29: 1626–31.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Clinical Diabetes Research, German Diabetes Center, Leibniz Center at Heinrich Heine University Düsseldorf, Auf’m Hennekamp 65, 40225, Düsseldorf, Germany

    F. ter Veld, B. Rose, S. Martin, C. Herder & K. Kempf PhD

  2. Department of General Pediatrics, University Children’s Hospital, Heinrich Heine University Düsseldorf, Düsseldorf

    F. ter Veld

  3. DeveloGen AG, Göttingen, Germany

    R. Mussmann

Authors
  1. F. ter Veld
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Rose
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Mussmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Herder
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. Kempf PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Kempf PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

ter Veld, F., Rose, B., Mussmann, R. et al. Effects of somatostatin and octreotide on cytokine and chemokine production by lipopolysaccharide-activated peripheral blood mononuclear cells. J Endocrinol Invest 32, 123–129 (2009). https://doi.org/10.1007/BF03345700

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345700

Key-words

Search

Navigation